Tandem Diabetes Care TNDM

Mr. Sheridan has served on our board of directors since June 2019 and as our President and Chief Executive Officer since March 2019. Prior to that, Mr. Sheridan served as our Executive Vice President and Chief Operating Officer since April 2013. Before joining our Company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc. Earlier in his career, Mr. Sheridan held various leadership roles including Executive Vice President of Research and Development and Operations for Volcano Corporation, Executive Vice President of Operations at CardioNet, Inc., and Vice President of Operations at Digirad Corporation. He previously served as a director of Acutus Medical, Inc. from March 2021 to April 2025. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University.

Leigh Vosseller has served as our Executive Vice President, Chief Financial Officer, and Treasurer since June 2018. She is responsible for our Company's financial functions and information technology. Ms. Vosseller held successive financial executive management positions since joining our Company in 2013. Before joining Tandem, she served as Vice President and Chief Financial Officer at Genoptix, and in financial leadership positions at Biosite. Since January 2021, Ms. Vosseller has served as a director and treasurer of Girls Inc. of San Diego, a non-profit organization that provides STEM-focused, research-based programming to underserved girls in the community. Ms. Vosseller is a certified public accountant (inactive) and holds a B.S. in Accounting from Missouri State University.

Elizabeth Gasser has served as our Executive Vice President and Chief Strategy and Product Officer since November 2023. She is responsible for our Company's strategy, business and corporate development, product management, user experience and competitive intelligence functions. From June 2021 to November 2023, Ms. Gasser served as our Executive Vice President and Chief Strategy Officer and as our Executive Vice President, Strategy and Corporate Development from January 2020 to June 2021. Before joining Tandem, Ms. Gasser served as an independent adviser providing strategic and corporate development solutions to boards and executive teams. Earlier in her career, she held various leadership roles including Vice President of Corporate Strategy at Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated. Ms. Gasser holds a B.A. and an M.A. in Economics from the University of Cambridge.

Shannon Hansen has served as our Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary since April 2024, and as our Chief Legal, Privacy & Compliance Officer and Secretary since August 2023. Ms. Hansen joined the Company as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary in January 2022 and throughout her tenure, she has maintained responsibility for the Company's legal, compliance and privacy functions. She also leads the cybersecurity function at Tandem. Before joining our Company, Ms. Hansen served as General Counsel, Corporate Secretary and Chief Privacy Officer at Alto Pharmacy from April 2020 to September 2021. Before her role at Alto Pharmacy, she held various leadership roles of increasing responsibility at Abbott Laboratories. From August 2021 until June 2025, Ms. Hansen served as an Independent External Audit and Supervisory Board Member for PHC Holdings Corporation. Earlier in her career, she was a partner at Kirkland & Ellis LLP, an Associate Solicitor at the United States Patent and Trademark Office and a process engineer at DuPont. Ms. Hansen holds a B.S. in Chemical Engineering from Carnegie Mellon University, and a J.D. from Stanford Law School.

Ms. Beaver has served on our board of directors since November 2025. Ms. Beaver has more than 20 years of strategic and operational finance experience globally and across many industries including healthcare, medical devices, gaming, enterprise technology and manufacturing. Ms. Beaver is the CFO at Lyra Health, a leading provider of mental health solutions, overseeing finance, accounting, investor relations, facilities, procurement and corporate development. Before starting this role in June 2025, she served as CFO at Evolus, a publicly traded medical aesthetics company, for three years. Before Evolus, Ms. Beaver held senior finance positions at global data and technology company, Experian, and global gaming company, IGT. Ms. Beaver holds a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.

Ms. Robertson has served as Chair of our board of directors since March 2023, and as a member of our board of directors since January 2019. Ms. Robertson is a founder and General Partner at Versant Ventures where she has specialized in investing in the areas of medical devices and diagnostics since 1999. In addition, through Longridge Business Advisors, she has provided business advisory services and board services since April 2017. Prior to Versant, she served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the critical care business unit in addition to leading the division's business development efforts. Prior to joining Chiron, Ms. Robertson was a co-founder and Vice President at Egis, a consumer products company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. Ms. Robertson holds a B.S. in Chemical Engineering from Cornell University.

Mr. Twomey has served on our board of directors since July 2013. Mr. Twomey has served as a director and chair of the audit committee of Bionano Genomics (Nasdaq: BNGO), a life sciences genome analysis instrumentation company since July 2018. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. He previously served as a director and chair of the audit committee for public companies, such as Senomyx and Cadence Pharmaceuticals, before their acquisitions. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara.

Dr. McGroddy-Goetz has served on our board of directors since June 2020. She has more than 25 years of experience leading global teams across business development, strategy, research and development, and product management. She has commercialized pioneering technologies spanning from microelectronics through cloud, advanced data analytics, artificial intelligence, hardware, software, and middleware with an emphasis on healthcare and life sciences applications. From October 2018 through June 2021, Dr. McGroddy-Goetz served as the Global Head of Strategic Partnerships at Medidata Solutions, a Dassault Systemes Company, where she also concurrently held other strategy, alliances and marketing executive roles. Previously, she held various leadership positions at IBM beginning in 1992, and most recently was Vice President, Strategy and Innovation, IBM Watson Health. She serves as an adjunct professor of healthcare informatics and administration at Sacred Heart University, and as board chair for Rides for Ridgefield, a non-profit organization dedicated to ensuring seniors and those with mobility disabilities maintain quality of life. Dr. McGroddy-Goetz holds a B.S. in Physics from SUNY Binghamton and a Ph.D. in Molecular Biophysics from Cornell University.

Mr. Sodhi has served on our board of directors since January 2021. He brings more than 25 years of global experience in informatics, artificial intelligence, information security, software services, and e-commerce solutions across the healthcare, financial services, and telecommunications sectors. Mr. Sodhi previously served as President of ResMed's software-as-a-service (SaaS) business from July 2017 to August 2021. Prior to that, he served as President of Healthcare Informatics (HI), where he led the development and expansion of ResMed's digital health and informatics solutions, helping advance the company's position as a global leader in digital health with a growing portfolio of device- and SaaS-based offerings. He joined ResMed in 2012 through the acquisition of Umbian Inc., a company he co-founded and served as President. Earlier in his career, he held senior leadership roles in the financial services sector, including Senior Vice President of Business Development and Chief Technology Officer at Skipjack Financial Services and co-founder and Chief Technology Officer of TransActive Ecommerce Solutions. Mr. Sodhi serves on the boards of Forefront Dermatology, EyeCare Partners, and NovaResp Technologies. He holds an MBA and a B.S. in Mathematics and Statistics from Dalhousie University.

Ms. Howell joined our board of directors in August 2020 and brings more than 30 years of pharmaceutical services and healthcare industry experience. Ms. Howell was appointed Chief Executive Officer of Parexel, a leading global clinical research organization servicing the life sciences industry, in May 2024 and also serves on the company's Board of Directors. She previously served as Parexel's Chief Operating and Growth Officer since September 2022, and as its Chief Commercial and Strategy Officer since May 2018. Before joining Parexel, Ms. Howell's healthcare industry experience included senior leadership positions with AmerisourceBergen (now Cencora), a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions. Before AmerisourceBergen, Ms. Howell was a founder of Lash Group and served as President for nearly 10 years following its acquisition by AmerisourceBergen. Ms. Howell currently serves on the board of directors for Catalyst and the Association of Clinical Research Organizations (ACRO). She holds a Master of Healthcare Administration from The Ohio State University and a Bachelor of Arts in Health Communications from the University of Illinois.

Mr. Malagueira has served on our board of directors since June 2022. He brings more than 25 years of experience in diabetes, medical devices and diagnostics solutions businesses with global corporations. Mr. Malagueira is currently President for three divisions at Hologic and responsible for the entire portfolio in the EMEA. Before starting this role in October 2023, he served as International Vice President, EMEA for three divisions at Hologic, since January 2019, and as International Vice President, EMEA and Canada, for the Hologic Diagnostics Solutions division, from June 2015 to December 2018. He possesses extensive experience and proven success of go-to-market models and strategies in Europe, Africa, CIS, and the Middle East. Before Hologic, Mr. Malagueira enjoyed more than 15 years at Johnson & Johnson, in commercial leading roles across EMEA, where he led successful turnarounds and market share growth of the diabetes solutions businesses, LifeScan and Animas. Mr. Malagueira holds an MBA and an Advanced Degree in Marketing from Catolica Lisbon School of Business and Economics. He holds an M.S. in Pharmaceutical Sciences and Clinical Analysis from University of Lisbon.

Mr. Cha has served on our board of directors since June 2022. He has more than 20 years of global experience across the healthcare value chain. Mr. Cha currently serves as Chief Product Officer at Verily where he leads product development. Before joining Verily in March 2024, he served as President and Chief Strategy Officer at Carbon Health from June 2021 to February 2024. He served as Head of Health Strategic Initiatives at Apple from August 2015 to May 2021 where he developed and led product initiatives and global strategic partnerships. Earlier in his career, Mr. Cha was a Principal and Co-Leader of the West Coast Strategy and Corporate Finance Practice as well as Co-Leader of the Healthcare Investor Practice at McKinsey & Company. Mr. Cha holds a JD from Harvard Law School, an MBA from Harvard Business School and an AB in Biochemical Sciences from Harvard College.

Rick Carpenter has served as our Executive Vice President and Chief Technology Officer since April 2026. He is responsible for our Company's engineering, research and development functions. From November 2021 to March 2026, Mr. Carpenter served as our Chief Technology Officer. Before joining our Company, Mr. Carpenter served from February 2020 to November 2021 as the Senior Vice President of Engineering at Inseego Corporation. Before that, Mr. Carpenter held leadership roles at Capsule Technologies and Qualcomm Life including General Manager of the IoMT Business and Senior Director of Engineering at Capsule Technologies, and Senior Director of Engineering at Qualcomm Life. Earlier in his career, he held various engineering development and leadership roles at Smith Micro Software, Nextwave Wireless, Sierra Wireless, General Dynamics, Motorola and Denso. Mr. Carpenter holds a B.S. in Computer Science from The University of Texas Permian Basin.

Susan Morrison has served as our Executive Vice President and Chief Administrative Officer since December 2017. She is responsible for our Company's investor relations, corporate communications, human resources and facilities functions. Ms. Morrison served in successive leadership positions for our Company since November 2007 and helped lead Tandem's transformation from a domestic venture-backed insulin pump start-up to a global diabetes technology company. Before joining Tandem, Ms. Morrison held leadership positions in Corporate and Investor Relations at Biosite Inc. Earlier in her career, she worked at both boutique and global public relations firms focused on healthcare, consumer products and crisis communications. Ms. Morrison holds a B.A. in Public Relations from Western Michigan University.

Jean-Claude JC Kyrillos has served as our Executive Vice President and Chief Operating Officer since June 2024. He is responsible for our Company's manufacturing operations, supply chain, quality and regulatory functions. Before joining Tandem, Mr. Kyrillos served in operating company president roles at Envista Holdings from February 2020 to June 2023, most recently serving as President of Diagnostics and Digital Solutions. Prior to that, he was Senior Vice President and General Manager at Qualcomm Life. Earlier in his career, Mr. Kyrillos held leadership roles at Becton Dickinson and ResMed Ventures, including Senior Vice President and General Manager of infusion solutions at Becton Dickinson and President of ResMed Ventures and Initiatives. He has served as an independent board director of San Diego Blood Bank since January 2016 and as Chair from January 2020 to December 2022. Mr. Kyrillos received a B.A. with Honors in History from Colgate University and an MBA from Harvard Business School.